MétaCan
Menu
Back to cohort
Record W4407975585 · doi:10.1016/j.jtct.2025.01.662

The Role of Second-HSCT for Children with Relapsed Hematological Malignancies: A Single Center Experience

2025· article· en· W4407975585 on OpenAlexaff
Chane Choed-Amphai, Deborah Tomlinson, Tal Schechter, Muhammad Ali, Yogi Chopra, Joerg Krueger

Bibliographic record

VenueTransplantation and Cellular Therapy · 2025
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsHospital for Sick Children
Fundersnot available
KeywordsSingle CenterMedicineCenter (category theory)PediatricsInternal medicine

Abstract

fetched live from OpenAlex

Background Allogeneic hematopoietic stem cell transplantation (HSCT) has become the standard of care for children with relapsed/refractory hematologic malignancies. Despite favorable outcomes, some patients experience relapsed/refractory disease after first-HSCT. With advancements of immunotherapies, less toxic conditioning regimens and expanded donor choices, second HSCT is being increasingly offered. However, data guiding selection of patients is scarce. This study aims to describe predictors of outcomes in children with relapsed/refractory hematologic malignancies after first-HSCT. Methods A retrospective review was conducted at The Hospital for Sick Children, Toronto, Canada. Children <18 years of age with hematologic malignancies who were diagnosed with relapsed/refractory disease after the first-HSCT between January 2008 and December 2023 were included. Descriptive statistics and Kaplan-Meier survival analyses were performed. A p-value <0.05 was considered statistically significant. Results Eighty-one children with relapsed/refractory hematologic malignancies after first-HSCT were included. The median age was 5.5 years (range, 0.1–15.6 years), the most common diagnosis was acute myeloid leukemia (49.4%), followed by acute lymphoblastic leukemia (37.0%). The median time from first-HSCT to relapse was 9 months (range, 1–108 months). With a median follow-up time of one-year, 3-year EFS was 35.1% (95%CI,24.8-45.6), OS was 36.4% (95%CI,26.0.0-46.9). A second-HSCT was performed in 32 cases (39.5%). Patients who received a second HSCT had a significant improved 3-year-EFS of 65.2% (95%CI,46.0-79.0) vs 15.2% (95%CI,6.6-26.9,p<0.001) and OS 68.3% (95%CI,49.1–81.6) vs 15.2% (95%CI,6.6–26.9,p < 0.001). Transplant related mortality was 8.6%. Number of relapses, previous graft-versus-host disease, switch of HSCT donor and time to relapse after first HSCT did not significantly affect outcomes. Limitations of the study include small number of patients and single institution setting. Conclusion Outcomes of children undergoing second-HSCT are favorable and should be considered for children who experience relapsed/refractory hematologic malignancies after first-HSCT. Additional research is needed to further define factors predicting treatment success.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.237
Teacher spread0.227 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractno

Explore more

Same venueTransplantation and Cellular TherapySame topicLymphoma Diagnosis and TreatmentFrench-language works237,207